To provide further information on MET as a potential target in SCLC, we studied the effects of a MET inhibitor in a panel of SCLC cell lines and also assayed the expression, activation state and mutational status of MET in a series of human SCLC specimens with complete clinical follow up. This evidence concerns the gene MET and small cell lung carcinoma.